Abridge has 6 close competitors: Neuralink, Alloy Therapeutics, Commure.
Sector, valuation and status for each competitor.
company profile›
competitor›
competitor›
competitor›
competitor›A private valuation and a public market cap share one column; each row names its basis and date.
AbridgeNeuralinkCommureHeartFlowInnovaccerAbridge builds an AI platform that turns clinician-patient conversations into structured clinical documentation, with tailored experiences for clinicians, revenue-cycle teams and nursing.
Abridge competes with 6 companies here: Neuralink, Alloy Therapeutics, Commure, HeartFlow, HistoSonics, Innovaccer.
Abridge was last valued at $5.3B (post-money, Apr 2026). That price was agreed in one transaction and holds until the next round. A listed competitor is repriced every trading session.
The closest healthcare technology and ai (ai-powered clinical documentation) peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Abridge is a private company; its shares do not trade on a public exchange.
The last valuation is $5.3B (post-money, Apr 2026).
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
